- Home
- HR vs MDGL Comparison
HR vs MDGL Comparison
Compare HR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HR
- MDGL
- Stock Information
- Founded
- HR 1992
- MDGL 2011
- Country
- HR United States
- MDGL United States
- Employees
- HR N/A
- MDGL N/A
- Industry
- HR Real Estate Investment Trusts
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- HR Real Estate
- MDGL Health Care
- Exchange
- HR Nasdaq
- MDGL Nasdaq
- Market Cap
- HR 5.3B
- MDGL 6.1B
- IPO Year
- HR 1993
- MDGL N/A
- Fundamental
- Price
- HR $17.96
- MDGL $417.43
- Analyst Decision
- HR Hold
- MDGL Strong Buy
- Analyst Count
- HR 7
- MDGL 10
- Target Price
- HR $17.67
- MDGL $474.67
- AVG Volume (30 Days)
- HR 4.0M
- MDGL 329.8K
- Earning Date
- HR 10-29-2025
- MDGL 10-30-2025
- Dividend Yield
- HR 5.31%
- MDGL N/A
- EPS Growth
- HR N/A
- MDGL N/A
- EPS
- HR N/A
- MDGL N/A
- Revenue
- HR $1,222,259,000.00
- MDGL $515,547,000.00
- Revenue This Year
- HR N/A
- MDGL $394.12
- Revenue Next Year
- HR $1.16
- MDGL $57.74
- P/E Ratio
- HR N/A
- MDGL N/A
- Revenue Growth
- HR N/A
- MDGL 3421.98
- 52 Week Low
- HR $14.09
- MDGL $200.63
- 52 Week High
- HR $18.82
- MDGL $457.16
- Technical
- Relative Strength Index (RSI)
- HR 59.55
- MDGL 54.19
- Support Level
- HR $17.75
- MDGL $418.36
- Resistance Level
- HR $18.43
- MDGL $440.90
- Average True Range (ATR)
- HR 0.33
- MDGL 13.63
- MACD
- HR -0.02
- MDGL -5.66
- Stochastic Oscillator
- HR 52.45
- MDGL 4.56
About HR Healthcare Realty Trust Incorporated
Healthcare Realty Trust Inc is a healthcare facility real estate investment trust. The company focuses on owning, leasing, and managing outpatient facilities and other healthcare properties. The company works to invest in outpatient facilities that are integral to a hospital's operations. It generates all of its revenue in the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.